ArticlePloS one2025
Economic impact and disease burden of COVID-19 in a tertiary care hospital: A three-year analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Challenges That Health Care Systems Faced During and After the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2026Article
- COVID-19 and Global Perinatal Health: Lessons Learned on Maternal-Neonatal Outcomes, Infant Feeding Practices, and Health Care Economics across Income Settings.American journal of perinatology · 2026Article
- Economic Analyses of COVID-19 Interventions: A Narrative Review of Global Evidence.Healthcare (Basel, Switzerland) · 2025Review
- Beyond the Virus: The Collateral Impact of COVID-19 on Antimicrobial Consumption, Microbial Resistance, and Pharmacoeconomics.Pathogens (Basel, Switzerland) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic has increased morbidity and mortality, along with substantial economic repercussions for healthcare systems and communities worldwide. This study describes the costs incurred by one of the biggest university hospitals in Finland during the first three years of the pandemic, from 2020 to 2022.
methodsA retrospective analysis was conducted at a 950-bed tertiary care hospital, encompassing data from 2020 to 2022. Hospitalized COVID-19 cases were identified from an automated surveillance program that integrated microbiological and administrative data. Patient-level data, including hospitalization demographics, vaccination status, and outcomes, were collected. Billing costs, indirect costs, and operational data were obtained to assess hospital costs comprehensively.
resultsDuring 2020-2022, 2 555 COVID-19-positive patients were treated at the hospital. Of them, 57% were hospitalized primarily for COVID-19 with the hospital billing costs of 14 492 399 € (median 4 137 €/ patient), and 47% of these costs were due to intensive care. Including ER visits of COVID-19 outpatients, admission screening and isolation costs of COVID-19 positive patients hospitalized for other reasons and indirect expenses, the total costs reached 28 899 298 € over three years. Additionally, the hospital incurred losses of income due to postponed elective surgeries. DISCUSSION: The economic burden of COVID-19 at the considered university hospital was substantial. Intensive care costs were a significant driver. This study provides a comprehensive overview of the economic and disease burden of COVID-19 at a tertiary care hospital, highlighting the need for strategic planning and financial readiness to address the costs associated with pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.